NASDAQ:IONS - Ionis Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $57.91
  • Forecasted Upside: 42.00 %
  • Number of Analysts: 15
  • Breakdown:
  • 2 Sell Ratings
  • 7 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$40.78
▼ -0.25 (-0.61%)
1 month | 3 months | 12 months
Get New Ionis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IONS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IONS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$57.91
▲ +42.00% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $57.91, with a high forecast of $86.00 and a low forecast of $33.00. The average price target represents a 42.00% upside from the last price of $40.78.
Hold
The current consensus among 15 investment analysts is to hold stock in Ionis Pharmaceuticals. This rating has held steady since August 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 1 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 1 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 1 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 1 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 2 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 2 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 2 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2021UBS GroupReiterated RatingReduceHigh
i
Rating by Esther Rajavelu at UBS Group AG
3/29/2021SVB LeerinkLower Price TargetMarket Perform$50.00 ➝ $36.00High
i
3/29/2021Morgan StanleyLower Price TargetUnderweight$50.00 ➝ $43.00N/A
i
3/29/2021Needham & Company LLCLower Price TargetBuy$95.00 ➝ $86.00N/A
i
3/29/2021BMO Capital MarketsLower Price TargetOutperform$90.00 ➝ $76.00N/A
i
3/23/2021BMO Capital MarketsLower Price TargetPositive ➝ Outperform$90.00 ➝ $76.00High
i
3/23/2021Needham & Company LLCLower Price TargetBuy$95.00 ➝ $86.00High
i
3/23/2021SVB LeerinkLower Price TargetMarket Perform$50.00 ➝ $36.00High
i
3/23/2021Morgan StanleyLower Price TargetUnderweight$50.00 ➝ $43.00High
i
3/23/2021BarclaysLower Price TargetEqual Weight$52.00 ➝ $47.00High
i
3/23/2021Royal Bank of CanadaLower Price TargetPositive ➝ Outperform$76.00 ➝ $65.00High
i
3/22/2021Piper SandlerLower Price TargetNeutral$55.00 ➝ $45.00High
i
3/16/2021UBS GroupReiterated RatingSell$33.00Medium
i
Rating by Esther Rajavelu at UBS Group AG
3/3/2021Morgan StanleyBoost Price TargetUnderweight$49.00 ➝ $50.00High
i
3/1/2021BarclaysUpgradeUnderweight ➝ Equal Weight$50.00 ➝ $52.00Low
i
2/25/2021Morgan StanleyBoost Price TargetUnderweight$49.00 ➝ $50.00High
i
2/24/2021Piper SandlerLower Price TargetNeutral$60.00 ➝ $55.00High
i
12/15/2020UBS GroupInitiated CoverageSell$34.00Medium
i
12/15/2020CowenUpgradeMarket Perform ➝ OutperformHigh
i
11/5/2020Morgan StanleyLower Price TargetUnderweight$50.00 ➝ $49.00High
i
11/5/2020SVB LeerinkLower Price TargetMarket Perform$56.00 ➝ $50.00High
i
10/13/2020Morgan StanleyLower Price TargetUnderweight$54.00 ➝ $50.00Low
i
10/7/2020OppenheimerReiterated RatingBuy$69.00Low
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
9/22/2020OppenheimerInitiated CoverageBuy$69.00High
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
9/22/2020Cantor FitzgeraldBoost Price TargetNeutral$56.00 ➝ $59.00High
i
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralMedium
i
9/8/2020CitigroupLower Price Target$74.00 ➝ $78.00Low
i
9/2/2020BenchmarkInitiated CoverageHoldMedium
i
9/1/2020Royal Bank of CanadaBoost Price Target$71.00 ➝ $73.00Low
i
9/1/2020SVB LeerinkBoost Price TargetMarket Perform$54.00 ➝ $56.00Medium
i
9/1/2020OppenheimerLower Price TargetOutperform$74.00 ➝ $69.00Medium
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
9/1/2020Needham & Company LLCBoost Price TargetBuy$89.00 ➝ $91.00Medium
i
Rating by Chad Messer at Needham & Company LLC
8/30/2020OppenheimerInitiated CoverageBuy$74.00High
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
8/10/2020CitigroupLower Price TargetBuy$80.00 ➝ $78.00High
i
8/6/2020Morgan StanleyLower Price TargetUnderweight$56.00 ➝ $54.00Low
i
8/6/2020OppenheimerReiterated RatingBuyLow
i
8/5/2020Needham & Company LLCInitiated CoverageBuy$89.00Low
i
Rating by Chad Messer at Needham & Company LLC
8/5/2020William BlairReiterated RatingHoldLow
i
Rating by Myles Minter at William Blair
7/15/2020Morgan StanleyBoost Price TargetUnderweight$51.00 ➝ $56.00Low
i
7/15/2020Needham & Company LLCReiterated RatingBuy$89.00Medium
i
Rating by Chad Messer at Needham & Company LLC
6/10/2020William BlairReiterated RatingHoldHigh
i
6/5/2020CitigroupBoost Price TargetBuy$71.00 ➝ $80.00High
i
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$71.00Medium
i
5/7/2020Morgan StanleyBoost Price TargetUnderweight$48.00 ➝ $51.00High
i
5/7/2020OppenheimerLower Price TargetOutperform$77.00 ➝ $74.00High
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
5/6/2020Needham & Company LLCReiterated RatingBuy$89.00High
i
Rating by Chad Messer at Needham & Company LLC
4/9/2020CitigroupLower Price TargetBuy$73.00 ➝ $71.00Low
i
3/26/2020Cantor FitzgeraldLower Price TargetNeutral$65.00 ➝ $56.00High
i
Rating by Eliana Merle at Cantor Fitzgerald
3/9/2020JPMorgan Chase & Co.Boost Price TargetNeutral$58.00 ➝ $60.00Low
i
3/5/2020CitigroupInitiated CoverageBuy$73.00High
i
2/27/2020Piper SandlerLower Price TargetNeutral$70.00 ➝ $65.00High
i
1/30/2020BMO Capital MarketsReiterated RatingBuy$86.00High
i
Rating by Do Kim at BMO Capital Markets
1/24/2020William BlairReiterated RatingHoldLow
i
Rating by M. Minter at William Blair
12/31/2019Bank of AmericaReiterated RatingBuy$70.00Medium
i
Rating by Jason Gerberry at Bank of America Co.
12/23/2019Needham & Company LLCReiterated RatingBuy$87.00Low
i
Rating by Chad Messer at Needham & Company LLC
12/13/2019Needham & Company LLCReiterated RatingBuy$87.00Medium
i
Rating by Chad Messer at Needham & Company LLC
12/12/2019OppenheimerInitiated CoverageBuy$77.00Low
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
11/14/2019William BlairInitiated CoverageMarket PerformLow
i
Rating by M. Minter at William Blair
11/13/2019Bank of AmericaInitiated CoverageBuy$70.00Medium
i
11/7/2019Piper Jaffray CompaniesLower Price TargetNeutral$75.00 ➝ $70.00Medium
i
Rating by Tyler Van Buren at Piper Jaffray Companies
11/7/2019Needham & Company LLCReiterated RatingBuy$87.00Low
i
Rating by Chad Messer at Needham & Company LLC
11/7/2019Morgan StanleyDowngradeEqual ➝ Equal Weight$63.00 ➝ $48.00Low
i
Rating by David Lebovitz at Morgan Stanley
11/7/2019CowenReiterated RatingHoldLow
i
10/16/2019CowenReiterated RatingHoldHigh
i
10/15/2019Cantor FitzgeraldSet Price TargetHold$65.00N/A
i
Rating by Eliana Merle at Cantor Fitzgerald
10/11/2019Morgan StanleyLower Price TargetEqual Weight$68.00 ➝ $63.00Medium
i
10/10/2019Wells Fargo & CompanyBoost Price TargetOutperform$90.00 ➝ $120.00Medium
i
10/9/2019Needham & Company LLCSet Price TargetBuy$87.00Low
i
Rating by Chad Messer at Needham & Company LLC
9/23/2019Wells Fargo & CompanyReiterated RatingBuyMedium
i
9/10/2019Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$80.00High
i
8/7/2019Evercore ISISet Price TargetHold$76.00Low
i
Rating by Joshua Schimmer at Evercore ISI
7/24/2019BMO Capital MarketsLower Price TargetOutperform$96.00 ➝ $95.00Low
i
5/24/2019Piper Jaffray CompaniesSet Price TargetHold$75.00Medium
i
Rating by Tyler Van Buren at Piper Jaffray Companies
4/24/2019Cantor FitzgeraldReiterated RatingHold$68.00Low
i
Rating by E. Merle at Cantor Fitzgerald
4/22/2019BMO Capital MarketsBoost Price TargetOutperform$96.00Low
i
4/18/2019Cantor FitzgeraldReiterated RatingHoldLow
i
Rating by E. Merle at Cantor Fitzgerald
4/9/2019Cantor FitzgeraldInitiated CoverageNeutral$68.00Medium
i
Rating by E. Merle at Cantor Fitzgerald
3/22/2019Piper Jaffray CompaniesSet Price TargetNeutral$63.00 ➝ $75.00Low
i
Rating by Tyler Van Buren at Piper Jaffray Companies
3/18/2019JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$47.00 ➝ $55.00Low
i
3/1/2019Morgan StanleySet Price TargetHold$71.00Low
i
Rating by David Lebovitz at Morgan Stanley
3/1/2019Piper Jaffray CompaniesSet Price TargetHold$63.00Low
i
Rating by Tyler Van Buren at Piper Jaffray Companies
2/28/2019Piper Jaffray CompaniesBoost Price TargetNeutral$60.00Low
i
Rating by Tyler Van Buren at Piper Jaffray Companies
2/28/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $82.00Low
i
11/27/2018SVB LeerinkInitiated CoverageMarket Perform$50.00High
i
Rating by M. Foroohar at SVB Leerink LLC
11/7/2018Morgan StanleySet Price TargetHold$46.00Low
i
Rating by David Lebovitz at Morgan Stanley
11/6/2018Piper Jaffray CompaniesSet Price TargetHold$50.00Medium
i
Rating by Tyler Van Buren at Piper Jaffray Companies
10/3/2018Morgan StanleySet Price TargetHold$45.00Low
i
Rating by David Lebovitz at Morgan Stanley
9/25/2018Stifel NicolausBoost Price TargetHold ➝ Hold$45.00 ➝ $48.00High
i
9/24/2018Piper Jaffray CompaniesSet Price TargetHold$50.00Medium
i
Rating by Tyler Van Buren at Piper Jaffray Companies
8/28/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$49.00 ➝ $45.00Low
i
8/28/2018Stifel NicolausLower Price TargetHold ➝ Hold$47.00 ➝ $45.00High
i
8/8/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $49.00High
i
8/7/2018Stifel NicolausLower Price TargetHold ➝ Hold$55.00 ➝ $48.00High
i
7/11/2018Piper Jaffray CompaniesSet Price TargetHold$50.00Low
i
Rating by Tyler Van Buren at Piper Jaffray Companies
6/20/2018BarclaysDowngradeEqual Weight ➝ Underweight$52.00High
i
5/30/2018Piper Jaffray CompaniesInitiated CoverageHold$50.00Medium
i
Rating by Tyler Van Buren at Piper Jaffray Companies
5/7/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$52.00Low
i
5/7/2018Stifel NicolausLower Price TargetHold ➝ Hold$57.00Low
i
4/23/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.00Medium
i
2/28/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$64.00 ➝ $65.00High
i
2/28/2018Stifel NicolausBoost Price TargetHold ➝ Hold$55.00 ➝ $57.00High
i
2/20/2018Sanford C. BernsteinReiterated RatingMarket Perform$61.00 ➝ $55.00Low
i
11/8/2017BMO Capital MarketsBoost Price TargetOutperform$64.00 ➝ $65.00N/A
i
11/8/2017Morgan StanleyBoost Price TargetEqual Weight$45.00 ➝ $49.00N/A
i
10/17/2017Needham & Company LLCReiterated RatingBuy$64.00N/A
i
10/13/2017Stifel NicolausReiterated RatingHold$50.00N/A
i
10/6/2017The Goldman Sachs GroupReiterated RatingSell ➝ Sell$30.00N/A
i
10/2/2017BMO Capital MarketsReiterated RatingOutperform$69.00Medium
i
9/21/2017BarclaysLower Price TargetEqual Weight$55.00 ➝ $52.00Low
i
9/17/2017Needham & Company LLCReiterated RatingBuy$64.00Low
i
9/12/2017Stifel NicolausReiterated RatingHoldLow
i
9/6/2017BarclaysInitiated CoverageEqual Weight$55.00Medium
i
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$65.00Low
i
8/14/2017LaidlawReiterated RatingBuy$65.00Low
i
8/14/2017BMO Capital MarketsBoost Price TargetOutperform$67.00 ➝ $69.00Low
i
8/10/2017Jefferies Financial GroupReiterated RatingUnderperform$17.00 ➝ $18.00High
i
8/9/2017Stifel NicolausBoost Price TargetHold$42.00 ➝ $50.00Low
i
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$57.00High
i
7/26/2017Needham & Company LLCReiterated RatingBuy$64.00Medium
i
7/25/2017BMO Capital MarketsReiterated RatingOutperform$59.56 ➝ $62.00Low
i
7/12/2017BMO Capital MarketsReiterated RatingOutperform$59.00 ➝ $62.00Low
i
7/10/2017Stifel NicolausReiterated RatingHold$42.00Medium
i
6/2/2017BMO Capital MarketsReiterated RatingBuy$59.00Medium
i
Rating by Do Kim at BMO Capital Markets
5/22/2017CowenReiterated RatingMarket PerformLow
i
5/17/2017SVB LeerinkReiterated RatingOutperform$47.00 ➝ $45.00Medium
i
5/17/2017Needham & Company LLCReiterated RatingBuy$64.00Low
i
5/11/2017BMO Capital MarketsBoost Price TargetOutperform$32.00 ➝ $35.00High
i
Rating by Do Kim at BMO Capital Markets
5/10/2017Piper Jaffray CompaniesSet Price TargetBuy$66.00 ➝ $51.00Low
i
Rating by Joshua Schimmer at Piper Jaffray Companies
4/26/2017BMO Capital MarketsReiterated RatingOutperform$59.00Low
i
Rating by Do Kim at BMO Capital Markets
3/10/2017The Goldman Sachs GroupDowngradeNeutral ➝ Sell$28.00 ➝ $25.00High
i
3/7/2017BMO Capital MarketsLower Price TargetOutperform$63.00 ➝ $59.00N/A
i
Rating by Do Kim at BMO Capital Markets
3/6/2017Needham & Company LLCReiterated RatingBuy$64.00N/A
i
2/28/2017Needham & Company LLCReiterated RatingBuy$64.00N/A
i
2/14/2017BMO Capital MarketsReiterated RatingOutperform ➝ Positive$63.00N/A
i
Rating by Do Kim at BMO Capital Markets
1/17/2017BMO Capital MarketsReiterated RatingOutperform$68.00 ➝ $63.00N/A
i
Rating by Do Kim at BMO Capital Markets
1/8/2017BMO Capital MarketsReiterated RatingOutperform$68.00N/A
i
Rating by Do Kim at BMO Capital Markets
1/8/2017Needham & Company LLCReiterated RatingBuy$64.00N/A
i
Rating by Chad Messer at Needham & Company LLC
1/6/2017CowenReiterated RatingHoldN/A
i
Rating by Eric Schmidt at Cowen Inc
1/6/2017Jefferies Financial GroupReiterated RatingSell$17.00N/A
i
1/5/2017Janney Montgomery ScottSet Price TargetHold$44.00N/A
i
Rating by Debjit Chattopadhyay at Janney Montgomery Scott
12/28/2016Janney Montgomery ScottReiterated RatingNeutral$50.00 ➝ $54.00N/A
i
12/28/2016BMO Capital MarketsBoost Price TargetOutperform$61.00 ➝ $68.00N/A
i
Rating by Do Kim at BMO Capital Markets
12/27/2016Needham & Company LLCReiterated RatingBuy$64.00N/A
i
Rating by Chad Messer at Needham & Company LLC
12/27/2016LaidlawBoost Price TargetBuy$59.00 ➝ $65.00N/A
i
12/27/2016SVB LeerinkBoost Price TargetMarket Perform$40.00 ➝ $47.00N/A
i
Rating by P. Matteis at SVB Leerink LLC
12/20/2016BMO Capital MarketsSet Price TargetBuy$48.00 ➝ $61.00N/A
i
Rating by Do Kim at BMO Capital Markets
11/10/2016JPMorgan Chase & Co.Reiterated RatingHold$35.00N/A
i
Rating by Jessica Fye at JPMorgan Chase & Co.
11/10/2016SVB LeerinkReiterated RatingMarket Perform$40.00N/A
i
Rating by P. Matteis at SVB Leerink LLC
11/10/2016Jefferies Financial GroupReiterated RatingSell$17.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
11/9/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by joshua schimmer at Piper Jaffray Companies
11/8/2016BMO Capital MarketsReiterated RatingBuy$48.00N/A
i
Rating by Do Kim at BMO Capital Markets
10/17/2016BMO Capital MarketsReiterated RatingOutperform$48.00N/A
i
Rating by Do Kim at BMO Capital Markets
10/6/2016BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$42.00 ➝ $48.00N/A
i
Rating by Do Kim at BMO Capital Markets
9/28/2016Janney Montgomery ScottInitiated CoverageBuy$47.00N/A
i
9/26/2016Piper Jaffray CompaniesReiterated RatingOverweight$46.00N/A
i
Rating by joshua schimmer at Piper Jaffray Companies
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
8/19/2016Wells Fargo & CompanyReiterated RatingOutperformN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
8/18/2016Piper Jaffray CompaniesReiterated RatingOverweight$46.00N/A
i
Rating by joshua schimmer at Piper Jaffray Companies
8/13/2016CowenReiterated RatingMarket PerformN/A
i
Rating by Eric Schmidt at Cowen Inc
8/11/2016SVB LeerinkReiterated RatingHold$36.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
8/10/2016Piper Jaffray CompaniesBoost Price TargetOverweight$36.00 ➝ $46.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
8/3/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
8/2/2016SVB LeerinkReiterated RatingMarket Perform$26.00 ➝ $36.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
8/2/2016BarclaysBoost Price TargetEqual Weight$26.00 ➝ $41.00N/A
i
8/2/2016Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$37.00 ➝ $37.00N/A
i
8/1/2016BMO Capital MarketsBoost Price TargetMarket Perform$25.00 ➝ $40.00N/A
i
Rating by Do Kim at BMO Capital Markets
8/1/2016Needham & Company LLCBoost Price TargetBuy$55.00 ➝ $64.00N/A
i
Rating by Chad Messer at Needham & Company LLC
7/18/2016SVB LeerinkReiterated RatingMarket Perform$39.00 ➝ $26.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
7/15/2016Jefferies Financial GroupReiterated RatingUnderperform$12.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
7/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$35.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
7/14/2016Needham & Company LLCReiterated RatingBuy$55.00N/A
i
Rating by Chad Messer at Needham & Company LLC
7/14/2016CowenReiterated RatingHoldN/A
i
Rating by Eric Schmidt at Cowen Inc
7/8/2016Needham & Company LLCReiterated RatingBuy$55.00N/A
i
Rating by Chad Messer at Needham & Company LLC
7/8/2016BMO Capital MarketsReiterated RatingMarket Perform$26.00N/A
i
Rating by Do Kim at BMO Capital Markets
6/10/2016Piper Jaffray CompaniesReiterated RatingBuy$35.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
6/7/2016Needham & Company LLCReiterated RatingBuy$55.00N/A
i
Rating by Chad Messer at Needham & Company LLC
6/7/2016BMO Capital MarketsReiterated RatingMarket Perform$26.00N/A
i
Rating by Do Kim at BMO Capital Markets
5/29/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by Jessica Fye at JPMorgan Chase & Co.
5/29/2016Jefferies Financial GroupReiterated RatingSellN/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
5/27/2016JPMorgan Chase & Co.Lower Price TargetNeutral$53.00 ➝ $25.00N/A
i
5/27/2016BarclaysLower Price TargetEqual Weight$42.00 ➝ $26.00N/A
i
5/27/2016BMO Capital MarketsDowngradeOutperform ➝ Market Perform$55.00 ➝ $26.00N/A
i
5/26/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
5/26/2016CowenReiterated RatingOutperform ➝ HoldN/A
i
Rating by Eric Schmidt at Cowen Inc
5/26/2016Needham & Company LLCReiterated RatingBuy$88.00 ➝ $55.00N/A
i
5/19/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
5/5/2016Piper Jaffray CompaniesReiterated RatingBuy$60.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
5/5/2016SVB LeerinkLower Price TargetMarket Perform$40.00 ➝ $39.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
5/4/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
5/2/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
(Data available from 4/19/2016 forward)
Ionis Pharmaceuticals logo
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Read More

Today's Range

Now: $40.78
$40.20
$41.31

50 Day Range

MA: $48.57
$40.87
$55.64

52 Week Range

Now: $40.78
$40.20
$64.37

Volume

1,860,200 shs

Average Volume

1,221,907 shs

Market Capitalization

$5.74 billion

P/E Ratio

84.96

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Ionis Pharmaceuticals?

The following equities research analysts have issued research reports on Ionis Pharmaceuticals in the last year: Barclays PLC, Benchmark Co., BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Cowen Inc, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, SVB Leerink LLC, TheStreet, UBS Group AG, William Blair, and Zacks Investment Research.
View the latest analyst ratings for IONS.

What is the current price target for Ionis Pharmaceuticals?

11 Wall Street analysts have set twelve-month price targets for Ionis Pharmaceuticals in the last year. Their average twelve-month price target is $57.91, suggesting a possible upside of 42.0%. Needham & Company LLC has the highest price target set, predicting IONS will reach $86.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $33.00 for Ionis Pharmaceuticals in the next year.
View the latest price targets for IONS.

What is the current consensus analyst rating for Ionis Pharmaceuticals?

Ionis Pharmaceuticals currently has 2 sell ratings, 7 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IONS, but not buy more shares or sell existing shares.
View the latest ratings for IONS.

What other companies compete with Ionis Pharmaceuticals?

How do I contact Ionis Pharmaceuticals' investor relations team?

Ionis Pharmaceuticals' physical mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company's listed phone number is 760-931-9200 and its investor relations email address is [email protected] The official website for Ionis Pharmaceuticals is www.ionispharma.com.